Literature DB >> 23695808

I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.

Carrie Printz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23695808     DOI： 10.1002/cncr.28172

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  9 in total

1.  Benchmarking the scientific output of the Innovative Medicines Initiative.

Authors:  Magda Gunn; Mark Lim; Didi Cross; Michel Goldman
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  Targeting the low-hanging fruit of neurodegeneration.

Authors:  Amanda R Mason; Adam Ziemann; Steven Finkbeiner
Journal:  Neurology       Date:  2014-10-14       Impact factor: 9.910

3.  Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.

Authors:  Lorna Rodriguez-Rodriguez; Kim M Hirshfield; Veronica Rojas; Robert S DiPaola; Darlene Gibbon; Mira Hellmann; Sara Isani; Aliza Leiser; Gregory M Riedlinger; Allison Wagreich; Siraj M Ali; Julia A Elvin; Vincent A Miller; Shridar Ganesan
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

Review 4.  Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Authors:  Z Fadoukhair; D Zardavas; M A Chad; T Goulioti; P Aftimos; M Piccart
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

5.  Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Authors:  John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

Review 6.  The rise of genomic profiling in ovarian cancer.

Authors:  Rebecca A Previs; Anil K Sood; Gordon B Mills; Shannon N Westin
Journal:  Expert Rev Mol Diagn       Date:  2016-12       Impact factor: 5.225

7.  Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.

Authors:  Jae-Hyun Park; Miran Jang; Yunus Emre Tarhan; Toyomasa Katagiri; Mitsunori Sasa; Yasuo Miyoshi; Krishna R Kalari; Vera J Suman; Richard Weinshilboum; Liewei Wang; Judy C Boughey; Matthew P Goetz; Yusuke Nakamura
Journal:  Int J Oncol       Date:  2016-05-27       Impact factor: 5.650

Review 8.  PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

Authors:  Anthony Gonçalves; Alexandre Bertucci; François Bertucci
Journal:  Cancers (Basel)       Date:  2020-05-27       Impact factor: 6.639

9.  New generation of breast cancer clinical trials implementing molecular profiling.

Authors:  Dimitrios Zardavas; Martine Piccart-Gebhart
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.